Literature DB >> 21607101

Microenvironment at tissue injury, a key focus for efficient stem cell therapy: A discussion of mesenchymal stem cells.

Pranela Rameshwar1.   

Abstract

Stem cell therapy is not a new field, as indicated by the success of hematopoietic stem cell reconstitution for various hematological malignancies and immune-mediated disorders. In the case of tissue repair, the major issue is whether stem cells should be implanted, regardless of the type and degree of injury. Mesenchymal stem cells have thus far shown evidence of safety, based on numerous clinical trials, particularly for immune-mediated disorders. The premise behind these trials is to regulate the stimulatory immune responses negatively. To apply stem cells for other disorders, such as acute injuries caused by insults from surgical trauma and myocardial infarction, would require other scientific considerations. This does not imply that such injuries are not accompanied by immune responses. Indeed, acute injuries could accompany infiltration of immune cells to the sites of injuries. The implantation of stem cells within a milieu of inflammation will establish an immediate crosstalk among the stem cells, microenvironmental molecules, and resident and infiltrating immune cells. The responses at the microenvironment of tissue injury could affect distant and nearby organs. This editorial argues that the microenvironment of any tissue injury is a key consideration for effective stem cell therapy.

Entities:  

Keywords:  Immune responses; Mesenchymal stem cells; Microenvironment; Stem cell therapy

Year:  2009        PMID: 21607101      PMCID: PMC3097910          DOI: 10.4252/wjsc.v1.i1.3

Source DB:  PubMed          Journal:  World J Stem Cells        ISSN: 1948-0210            Impact factor:   5.326


  36 in total

1.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

2.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

Review 3.  Mesenchymal stem cells: biology and potential clinical uses.

Authors:  R J Deans; A B Moseley
Journal:  Exp Hematol       Date:  2000-08       Impact factor: 3.084

4.  Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens.

Authors:  Julius A Potian; Hana Aviv; Nicholas M Ponzio; Jonathan S Harrison; Pranela Rameshwar
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

5.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  Human bone marrow angiogenesis: in vitro modulation by substance P and neurokinin A.

Authors:  Laurent Pelletier; Regis Angonin; Jacques Regnard; Dominique Fellmann; Pierre Charbord
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

Review 7.  The relationship of aplastic anemia and PNH.

Authors:  Neal S Young; Jaroslaw P Maciejewski; Elaine Sloand; Guiben Chen; Weihua Zeng; Antonio Risitano; Akira Miyazato
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

Authors:  S M Devine; A M Bartholomew; N Mahmud; M Nelson; S Patil; W Hardy; C Sturgeon; T Hewett; T Chung; W Stock; D Sher; S Weissman; K Ferrer; J Mosca; R Deans; A Moseley; R Hoffman
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

9.  Bone marrow failure following severe injury in humans.

Authors:  David H Livingston; Devashish Anjaria; Jonathan Wu; Carl J Hauser; Victor Chang; Edwin A Deitch; Pranela Rameshwar
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

10.  Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor.

Authors:  Hai-Feng Duan; Chu-Tse Wu; Dan-Li Wu; Ying Lu; Hong-Jun Liu; Xiao-Qin Ha; Qun-Wei Zhang; Hua Wang; Xiang-Xu Jia; Li-Sheng Wang
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

View more
  5 in total

1.  Post implantation fate of adipogenic induced mesenchymal stem cells on Type I collagen scaffold in a rat model.

Authors:  Balu Venugopal; Francis B Fernandez; V S Harikrishnan; Annie John
Journal:  J Mater Sci Mater Med       Date:  2017-01-20       Impact factor: 3.896

2.  Tumor necrosis factor-α/CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice.

Authors:  Somayeh Shahrokhi; Saeed Daneshmandi; Farid Menaa
Journal:  Hum Gene Ther       Date:  2014-03-04       Impact factor: 5.695

3.  Ultrastructure Morphological Characterization of Different Passages of Rat Dental Follicle Stem Cells at In vitro Culture.

Authors:  Fakhri A Al-Bagdadi; Humberto M Barona; Eduardo Martinez-Ceballos; Shaomian Yao
Journal:  J Microsc Ultrastruct       Date:  2019 Apr-Jun

4.  Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart.

Authors:  Stephanie Buccini; Khawaja Husnain Haider; Rafeeq P H Ahmed; Shujia Jiang; Muhammad Ashraf
Journal:  Basic Res Cardiol       Date:  2012-10-18       Impact factor: 17.165

Review 5.  Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

Authors:  Patricia Rieken Macêdo Rocco; Bruno Solano de Freitas Souza; Kátia Nunes da Silva; André Luiz Nunes Gobatto; Zaquer Suzana Munhoz Costa-Ferro; Bruno Raphael Ribeiro Cavalcante; Alex Cleber Improta Caria; Luciana Souza de Aragão França; Carolina Kymie Vasques Nonaka; Fernanda de Macêdo Lima; Miquéias Lopes-Pacheco
Journal:  Stem Cell Res Ther       Date:  2021-07-27       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.